Prognostic impact of lung adenocarcinoma second predominant pattern from a large European database.


Journal

Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643

Informations de publication

Date de publication:
Feb 2021
Historique:
received: 16 09 2020
revised: 28 10 2020
accepted: 29 10 2020
pubmed: 11 11 2020
medline: 5 3 2021
entrez: 10 11 2020
Statut: ppublish

Résumé

Adenocarcinoma patterns could be grouped based on clinical behaviors: low- (lepidic), intermediate- (papillary or acinar), and high-grade (micropapillary and solid). We analyzed the impact of the second predominant pattern (SPP) on disease-free survival (DFS). We retrospectively collected data of surgically resected stage I and II adenocarcinoma. anatomical resection with lymphadenectomy and pathological N0. Pure adenocarcinomas and mucinous subtypes were excluded. Recurrence rate and factors affecting DFS were analyzed according to the SPP focusing on intermediate-grade predominant pattern adenocarcinomas. Among 270 patients, 55% were male. The mean age was 68.3 years. SPP pattern appeared as follows: lepidic 43.0%, papillary 23.0%, solid 14.4%, acinar 11.9%, and micropapillary 7.8%. The recurrence rate was 21.5% and 5-year DFS was 71.1%. No difference in DFS was found according to SPP (p = .522). In patients with high-grade SPP, the percentage of SPP, age, and tumor size significantly influenced DFS (p = .016). In patients with lepidic SPP, size, male gender, and lymph-node sampling (p = .005; p = .014; p = .038, respectively) significantly influenced DFS. The impact of SPP on DFS is not homogeneous in a subset of patients with the intermediate-grade predominant patterns. The influence of high-grade SPP on DFS is related to its proportion in the tumor.

Sections du résumé

BACKGROUND AND OBJECTIVES OBJECTIVE
Adenocarcinoma patterns could be grouped based on clinical behaviors: low- (lepidic), intermediate- (papillary or acinar), and high-grade (micropapillary and solid). We analyzed the impact of the second predominant pattern (SPP) on disease-free survival (DFS).
METHODS METHODS
We retrospectively collected data of surgically resected stage I and II adenocarcinoma.
SELECTION CRITERIA METHODS
anatomical resection with lymphadenectomy and pathological N0. Pure adenocarcinomas and mucinous subtypes were excluded. Recurrence rate and factors affecting DFS were analyzed according to the SPP focusing on intermediate-grade predominant pattern adenocarcinomas.
RESULTS RESULTS
Among 270 patients, 55% were male. The mean age was 68.3 years. SPP pattern appeared as follows: lepidic 43.0%, papillary 23.0%, solid 14.4%, acinar 11.9%, and micropapillary 7.8%. The recurrence rate was 21.5% and 5-year DFS was 71.1%. No difference in DFS was found according to SPP (p = .522). In patients with high-grade SPP, the percentage of SPP, age, and tumor size significantly influenced DFS (p = .016). In patients with lepidic SPP, size, male gender, and lymph-node sampling (p = .005; p = .014; p = .038, respectively) significantly influenced DFS.
CONCLUSIONS CONCLUSIONS
The impact of SPP on DFS is not homogeneous in a subset of patients with the intermediate-grade predominant patterns. The influence of high-grade SPP on DFS is related to its proportion in the tumor.

Identifiants

pubmed: 33169397
doi: 10.1002/jso.26292
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

560-569

Informations de copyright

© 2020 Wiley Periodicals LLC.

Références

Zhang R, Chen C, Dong X, et al. Independent validation of early-stage NSCLC prognostic scores incorporating epigenetic and transcriptional biomarkers with gene-gene interactions and main effects. Chest. 2020;158:808-819. https://doi.org/10.1016/j.chest.2020.01.048
Travis WD, Brambilla E, Noguchi M, et al. International Association for the study of lung cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of lung adenocarcinoma. J Thorac Oncol. 2011;6(2):244-285. https://doi.org/10.1097/JTO.0b013e318206a22
Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization Classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 Classification. J Thorac Oncol. 2015;10(9):1243-1260. https://doi.org/10.1097/JTO.0000000000000630
Sica G, Yoshizawa A, Sima CS, et al. A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol. 2010;34(8):1155-1162. https://doi.org/10.1097/PAS.0b013e3181e4ee32
Warth A, Muley T, Meister M, et al. The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol. 2012;30(13):1438-1446. https://doi.org/10.1200/JCO.2011.37.2185
Hung JJ, Jeng WJ, Chou TY, et al. Prognostic value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification on death and recurrence in completely resected stage I lung adenocarcinoma. Ann Surg. 2013;258(6):1079-1086. https://doi.org/10.1097/SLA.0b013e31828920c0
Russell PA, Wainer Z, Wright GM, Daniels M, Conron M, Williams RA. Does lung adenocarcinoma subtype predict patient survival?: A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International multidisciplinary lung adenocarcinoma classification. J Thorac Oncol. 2011;6(9):1496-1504. https://doi.org/10.1097/JTO.0b013e318221f701
Ito M, Miyata Y, Yoshiya T, et al. Second predominant subtype predicts outcomes of intermediate-malignant invasive lung adenocarcinoma†. Eur J Cardiothorac Surg. 2017;51(2):218-222. https://doi.org/10.1093/ejcts/ezw318
Lardinois D, De Leyn P, Vanschil P, et al. ESTS guidelines for intraoperative lymph node staging in non-small-cell lung cancer. Eur J Cardiothorac Surg. 2006;30:787-792.
Nitadori J, Bograd AJ, Kadota K, et al. Impact of micropapillary histologic subtype in selecting limited resection vs lobectomy for lung adenocarcinoma of 2cm or smaller. J Natl Cancer Inst. 2013;105(16):1212-1220. https://doi.org/10.1093/jnci/djt166
Aprile V, Bertoglio P, Dini P, et al. Is left upper lobectomy always worthwhile for early stage lung cancer? A comparison between left upper lobectomy, trisegmentectomy, and lingulectomy. J Surg Oncol. 2018;117(4):618-624. https://doi.org/10.1002/jso.24884
Hung JJ, Yeh YC, Jeng WJ, et al. Predictive value of the international association for the study of lung cancer/American Thoracic Society/European Respiratory Society classification of lung adenocarcinoma in tumor recurrence and patient survival. J Clin Oncol. 2014;32(22):2357-2364. https://doi.org/10.1200/JCO.2013.50.1049
Travis WD, Brambilla E, Muller-Hemerlinch HK, Curtis CH. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press; 2004.
Motoi N, Szoke J, Riely GJ, et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol. 2008;32(6):810-827. https://doi.org/10.1097/PAS.0b013e31815cb162
Lee G, Choi ER, Lee HY, et al. Pathologic heterogeneity of lung adenocarcinomas: a novel pathologic index predicts survival. Oncotarget. 2016;7(43):70353-70363. https://doi.org/10.18632/oncotarget.11857
Mansuet-Lupo A, Bobbio A, Blons H, et al. The new histologic classification of lung primary adenocarcinoma subtypes is a reliable prognostic marker and identifies tumors with different mutation status: the experience of a French cohort. Chest. 2014;146(3):633-643. https://doi.org/10.1378/chest.13-2499
Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol. 2011;24(5):653-664. https://doi.org/10.1038/modpathol.2010.232
De Leyn P, Lardinois D, Van Schil P, et al. European trends in preoperative and intraoperative nodal staging: ESTS guidelines. J Thorac Oncol. 2007;2(4):357-361.
Cha MJ, Lee HY, Lee KS, et al. Micropapillary and solid subtypes of invasive lung adenocarcinoma: clinical predictors of histopathology and outcome. J Thorac Cardiovasc Surg. 2014;147(3):921-928. https://doi.org/10.1016/j.jtcvs.2013.09.045
Sumiyoshi S, Yoshizawa A, Sonobe M, et al. Pulmonary adenocarcinomas with micropapillary component significantly correlate with recurrence, but can be well controlled with EGFR tyrosine kinase inhibitors in the early stages. Lung Cancer. 2013;81(1):53-59. https://doi.org/10.1016/j.lungcan.2013.04.003
Koga K, Hamasaki M, Kato F, et al. Association of c-Met phosphorylation with micropapillary pattern and small cluster invasion in pT1-size lung adenocarcinoma. Lung Cancer. 2013;82(3):413-419. https://doi.org/10.1016/j.lungcan.2013.09.005
Ventura L, Carbognani P, Gnetti L, et al. Multiple primary malignancies involving lung cancer: a single-center experience [published online ahead of print June 24, 2020]. Tumori. http://dx.doi.org/10.1177/0300891620933678

Auteurs

Pietro Bertoglio (P)

Division of Thoracic Surgery, IRCCS Sacro Cuore Don Calabria Hospital, Verona, Italy.

Giulia Querzoli (G)

Division of Pathological Anatomy, IRCCS Sacro Cuore Don Calabria Hospital, Verona, Italy.

Luigi Ventura (L)

Division of Thoracic Surgery, University Hospital of Parma, Parma, Italy.

Vittorio Aprile (V)

Division of Thoracic Surgery, University Hospital of Pisa, Pisa, Italy.

Maria A Cattoni (MA)

Division of Thoracic Surgery, University of Insubria, Varese, Italy.

Dania Nachira (D)

Department of General Thoracic Surgery, Fondazione Policlinico "A.Gemelli" - Catholic, University of Sacred Heart, Rome, Italy.

Filippo Lococo (F)

Department of General Thoracic Surgery, Fondazione Policlinico "A.Gemelli" - Catholic, University of Sacred Heart, Rome, Italy.

Maria Rodriguez Perez (M)

Division of Thoracic Surgery, Clinica Universidad de Navarra, Madrid, Spain.

Francesco Guerrera (F)

Division of Thoracic Surgery, University of Torino, Torino, Italy.

Fabrizio Minervini (F)

Division of Thoracic Surgery, Cantonal Hospital Lucerne, Lucerne, Switzerland.

Letizia Gnetti (L)

Division of Pathological Anatomy, University Hospital of Parma, Parma, Italy.

Diana Bacchin (D)

Division of Thoracic Surgery, University Hospital of Pisa, Pisa, Italy.

Francesca Franzi (F)

Division of Pathological Anatomy, University of Insubria, Varese, Italy.

Guido Rindi (G)

Division of Pathological Anatomy, Fondazione Policlinico "A.Gemelli" - Catholic, University of Sacred Heart, Rome, Italy.

Salvatore Bellafiore (S)

Division of Pathological Anatomy, Azienda USL di Reggio Emilia-IRCCS, Reggio Emilia, Italy.

Federico Femia (F)

Division of Thoracic Surgery, University of Torino, Torino, Italy.

Andrea Viti (A)

Division of Thoracic Surgery, IRCCS Sacro Cuore Don Calabria Hospital, Verona, Italy.

Giuseppe S Bogina (GS)

Division of Pathological Anatomy, IRCCS Sacro Cuore Don Calabria Hospital, Verona, Italy.

Peter Kestenholz (P)

Division of Thoracic Surgery, Cantonal Hospital Lucerne, Lucerne, Switzerland.

Enrico Ruffini (E)

Division of Thoracic Surgery, University of Torino, Torino, Italy.

Massimiliano Paci (M)

Division of Thoracic Surgery, Azienda USL di Reggio Emilia-IRCCS, Reggio Emilia, Italy.

Stefano Margaritora (S)

Department of General Thoracic Surgery, Fondazione Policlinico "A.Gemelli" - Catholic, University of Sacred Heart, Rome, Italy.

Andrea S Imperatori (AS)

Division of Thoracic Surgery, University of Insubria, Varese, Italy.

Marco Lucchi (M)

Division of Thoracic Surgery, University Hospital of Pisa, Pisa, Italy.

Luca Ampollini (L)

Division of Thoracic Surgery, University Hospital of Parma, Parma, Italy.

Alberto C Terzi (AC)

Division of Thoracic Surgery, IRCCS Sacro Cuore Don Calabria Hospital, Verona, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH